The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease

Brain

Volumn 140, Issue 1, 2017, Pages 118-131

  Acosta Cabronero, Julio ^a   Cardenas Blanco, Arturo ^a   Betts, Matthew J ^a   Butryn, Michaela ^b   Valdes Herrera, Jose P ^a   Galazky, Imke ^b   Nestor, Peter J ^a  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Biomarkers; Cellular mechanisms; Movement disorders; Oxidative stress; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; IRON;

ADULT; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN MAPPING; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORTICAL THICKNESS (BRAIN); DENTATE NUCLEUS; DIFFUSION TENSOR IMAGING; FEMALE; GLOBUS PALLIDUS; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE RECONSTRUCTION; MAGNETISM; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; VENTRAL REGION; VOLUMETRY; VOXEL BASED MORPHOMETRY; AGED; CEREBELLUM NUCLEUS; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PROCEDURES;

AGED; CEREBELLAR NUCLEI; FEMALE; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 85017521199     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww278     Document Type: Article

References (65)

1. Acosta-Cabronero J, Betts MJ, Cardenas-Blanco A, Yang S, Nestor PJ. In Vivo MRI mapping of brain iron deposition across the adult lifespan. J Neurosci 2016; 36: 364-74.
2. Ayton S, Lei P. Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed Res Int 2014; 2014: 581256.
3. Barbosa JH, Santos AC, Tumas V, Liu M, Zheng W, Haacke EM, et al. Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2 Magn Reson Imaging 2015; 33: 559-65.
4. Betts MJ, Acosta-Cabronero J, Cardenas-Blanco A, Nestor PJ, Duezel E. High-resolution characterisation of the aging brain using simultaneous quantitative susceptibility mapping (QSM) and R2 measurements at 7 T. Neuroimage 2016; 138: 43-63.
5. Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, Bajaj N, et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 2013; 81: 534-40.
6. Bostan AC, Dum RP, Strick PL. Cerebellar networks with the cerebral cortex and basal ganglia. Trends Cogn Sci 2013; 17: 241-54.
7. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
8. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-34.
9. Chen JC, Hardy PA, Kucharczyk W, Clauberg M, Joshi JG, Vourlas A, et al. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol 1993; 14: 275-81.
10. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999; 122: 1437-48.
11. Davies KM, Bohic S, Carmona A, Ortega R, Cottam V, Hare DJ, et al. Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiol Aging 2014; 35: 858-66.
12. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114: 1953-75.
13. Du G, Lewis MM, Shaffer ML, Chen H, Yang QX, Mailman RB, et al. Serum cholesterol and nigrostriatal R2 values in Parkinson's disease. PLoS One 2012; 7: e35397.
14. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
16. Fukunaga M, Li TQ, van Gelderen P, de Zwart JA, Shmueli K, Yao B, et al. Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proc Natl Acad Sci USA 2010; 107: 3834-9.
17. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992; 593: 343-6.
18. Griffiths PD, Dobson BR, Jones GR, Clarke DT. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999; 122: 667-73.
19. Griswold MA, Jakob PM, Heidemann RM, Nittka M, Jellus V, Wang J, et al. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med 2002; 47: 1202-10.
20. Groeger A, Berg D. Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies. J Neural Transm 2012; 119: 1523-8.
21. Guan X, Xuan M, Gu Q, Huang P, Liu C, Wang N, et al. Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping. NMR Biomed 2016, in Press. DOI: 10.1002/nbm.3489, available online 8 February 2016.
22. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958; 3: 41-51.
23. Han YH, Lee JH, Kang BM, Mun CW, Baik SK, Shin YI, et al. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. J Neurol Sci 2013; 325: 29-35.
24. Hare DJ, Double KL. Iron and dopamine: a toxic couple. Brain 2016; 139 (Pt 4): 1026-35. DOI: 10.1093/brain/aww022, available online 8 March 2016.
25. Hare DJ, Gerlach M, Riederer P. Considerations for measuring iron in post-mortem tissue of Parkinson's disease patients. J Neural Transm 2012; 119: 1515-21.
26. He N, Huang P, Ling H, Langley J, Liu C, Ding B, et al. Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease. NMR Biomed 2016, in Press. DOI: 10.1002/nbm.3554, available online 18 May 2016.
27. He N, Ling H, Ding B, Huang J, Zhang Y, Zhang Z, et al. Regionspecific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. Hum Brain Mapp 2015; 36: 4407-20.
28. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988; 334: 345-8.
29. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
30. Jack CR Jr, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology 1989; 172: 549-54.
31. Kim TH, Lee JH. Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study. PLoS One 2014; 9: e112512.
32. Klein A, Tourville J. 101 labeled brain images and a consistent human cortical labeling protocol. Front Neurosci 2012; 6: 171.
33. Krebs N, Langkammer C, Goessler W, Ropele S, Fazekas F, Yen K, et al. Assessment of trace elements in human brain using inductively coupled plasma mass spectrometry. J Trace Elem Med Biol 2014; 28: 1-7.
34. Kwon DH, Kim JM, Oh SH, Jeong HJ, Park SY, Oh ES, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012; 71: 267-77.
35. Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 2012; 62: 1593-9.
36. Lehericy S, Bardinet E, Poupon C, Vidailhet M, Francois C. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Mov Disord 2014; 29: 1574-81.
37. Li W, Jiang H, Song N, Xie J. Oxidative stress partially contributes to iron-induced alpha-synuclein aggregation in SK-N-SH cells. Neurotox Res 2011; 19: 435-42.
38. Liu T, Wisnieff C, Lou M, Chen W, Spincemaille P, Wang Y. Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping. Magn Reson Med 2013; 69: 467-76.
39. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008; 70: 1411-7.
40. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001; 50: 358-65.
41. Murakami Y, Kakeda S, Watanabe K, Ueda I, Ogasawara A, Moriya J, et al. Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease. AJNR Am J Neuroradiol 2015; 36: 1102-8.
42. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007; 68: 1820-5.
43. Ofori E, Pasternak O, Planetta PJ, Li H, Burciu RG, Snyder AF, et al. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease. Brain 2015; 138: 2322-31.
44. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 2000; 20: 6048-54.
45. Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011; 56: 907-22.
46. Pengas G, Pereira JM, Williams GB, Nestor PJ. Comparative reliability of total intracranial volume estimation methods and the influence of atrophy in a longitudinal semantic dementia cohort. J Neuroimaging 2009; 19: 37-46.
47. Planetta PJ, Ofori E, Pasternak O, Burciu RG, Shukla P, DeSimone JC, et al. Free-water imaging in Parkinson's disease and atypical parkinsonism. Brain 2016; 139: 495-508.
48. Popescu BF, George MJ, Bergmann U, Garachtchenko AV, Kelly ME, McCrea RP, et al. Mapping metals in Parkinson's and normal brain using rapid-scanning x-ray fluorescence. Phys Med Biol 2009; 54: 651-63.
49. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989; 52: 515-20.
50. Schofield MA, Zhu Y. Fast phase unwrapping algorithm for interferometric applications. Opt Lett 2003; 28: 1194-6.
51. Schwarz ST, Afzal M, Morgan PS, Bajaj N, Auer DP. Nigrosome imaging with T2 -weighted 3T MRI as a diagnostic marker of Parkinson's disease: a case-control and cross-sectional study of diagnostic accuracy. Lancet 2014; 383: s94.
52. Schweser F, Deistung A, Lehr BW, Reichenbach JR. Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: an approach to in vivo brain iron metabolism? Neuroimage 2011; 54: 2789-807.
53. Sian-Huelsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 2011; 118: 939-57.
54. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006; 31: 1487-505.
55. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009; 44: 83-98.
56. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991; 56: 978-82.
57. Stuber C, Morawski M, Schaefer A, Labadie C, Waehnert M, Leuze C, et al. Myelin and iron concentration in the human brain: a quantitative study of MRI contrast. Neuroimage 2014; 93: 95-106
58. Sun H, Walsh AJ, Lebel RM, Blevins G, Catz I, Lu JQ, et al. Validation of quantitative susceptibility mapping with Perls' iron staining for subcortical gray matter. Neuroimage 2015; 105: 486-92.
59. Walsh DO, Gmitro AF, Marcellin MW. Adaptive reconstruction of phased array MR imagery. Magn Reson Med 2000; 43: 682-90.
60. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 2014; 13: 1045-60.
61. Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007; 130: 708-19.
62. Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage 2014; 92: 381-97.
63. Worker A, Blain C, Jarosz J, Chaudhuri KR, Barker GJ, Williams SC, et al. Diffusion tensor imaging of Parkinson's disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study. PLoS One 2014; 9: e112638.
64. Wu T, Hallett M. The cerebellum in Parkinson's disease. Brain 2013; 136: 696-709.
65. Zheng W, Nichol H, Liu S, Cheng YC, Haacke EM. Measuring iron in the brain using quantitative susceptibility mapping and X-ray fluorescence imaging. Neuroimage 2013; 78: 68-74.